Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decitabine in chronic leukemias.

Jean-Pierre J Issa1, John C Byrd

  • 1Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. jpissa@mdanderson.org

Seminars in Hematology
|July 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS.

Blood neoplasia·2026
Same author

EZH2 and intracellular Ca<sup>2+</sup> signals interdependently coordinate alloreactive and CAR-T-cell responses.

Cellular & molecular immunology·2026
Same author

Modeling age-related methylation changes in vitro with intestinal organoids.

BMC biology·2026
Same author

DNA Methylation, Aging, and Cancer.

Epigenomes·2025
Same author

A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML.

Blood neoplasia·2025
Same author

ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer.

Cancer research·2025
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

5-Aza-2'-deoxycitidine (decitabine) is a DNA hypomethylating agent effective in myeloid malignancies. It shows promise for chronic leukemias, with ongoing trials in chronic lymphocytic leukemia and positive results in chronic myelogenous leukemia.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • 5-Aza-2 -deoxycitidine (decitabine) is a DNA hypomethylating agent.
  • Decitabine has demonstrated efficacy in myeloid malignancies like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
  • Aberrant DNA methylation is implicated in chronic leukemias, suggesting decitabine as a potential therapeutic strategy.

Purpose of the Study:

  • To investigate the efficacy of decitabine in chronic leukemias.
  • To evaluate molecular, hematologic, and cytogenetic responses to decitabine in chronic myelogenous leukemia (CML).
  • To explore the potential of decitabine in treating imatinib-resistant CML and ongoing trials in chronic lymphocytic leukemia (CLL).

Main Methods:

  • Review of clinical data and trial results for decitabine in chronic leukemias.

Related Experiment Videos

  • Assessment of molecular hypomethylation, hematologic, and cytogenetic responses.
  • Analysis of patient outcomes in various phases of CML, including those resistant to imatinib.

    • Main Results:

    • Decitabine induces molecular (hypomethylation), hematologic, and cytogenetic responses in chronic myelogenous leukemia (CML).
    • Positive responses observed in CML patients, including those refractory to imatinib mesylate.
    • Clinical trials for decitabine in chronic lymphocytic leukemia (CLL) are currently in progress.

    Conclusions:

    • Decitabine demonstrates proof-of-concept as a hypomethylating agent in chronic leukemias.
    • Further research is needed to optimize decitabine treatment for chronic leukemias.
    • Hypomethylating agents hold significant potential for improving patient outcomes in chronic leukemias.